Literature DB >> 25806176

EGFR TKIs as maintenance therapy in NSCLC: Finding the old in the new INFORMation.

Lorenza Landi1, Federico Cappuzzo1.   

Abstract

Entities:  

Year:  2012        PMID： 25806176      PMCID： PMC4367567          DOI： 10.3978/j.issn.2218-6751.2012.06.05

Source DB:  PubMed          Journal:  Transl Lung Cancer Res        ISSN： 2218-6751


× No keyword cloud information.
  11 in total

Review 1.  Maintenance treatment of advanced non-small-cell lung cancer: results of an international expert panel meeting of the Italian association of thoracic oncology.

Authors:  Cesare Gridelli; Filippo de Marinis; Massimo Di Maio; Andrea Ardizzoni; Chandra P Belani; Federico Cappuzzo; Fortunato Ciardiello; Panagiotis Fidias; Luis Paz-Ares; Francesco Perrone; Robert Pirker; Luigi De Petris; Rolf Stahel
Journal:  Lung Cancer       Date:  2012-01-21       Impact factor: 5.705

2.  Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial.

Authors:  Luis Paz-Ares; Filippo de Marinis; Mircea Dediu; Michael Thomas; Jean-Louis Pujol; Paolo Bidoli; Olivier Molinier; Tarini Prasad Sahoo; Eckart Laack; Martin Reck; Jesús Corral; Symantha Melemed; William John; Nadia Chouaki; Annamaria H Zimmermann; Carla Visseren-Grul; Cesare Gridelli
Journal:  Lancet Oncol       Date:  2012-02-16       Impact factor: 41.316

3.  Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR.

Authors:  Makoto Maemondo; Akira Inoue; Kunihiko Kobayashi; Shunichi Sugawara; Satoshi Oizumi; Hiroshi Isobe; Akihiko Gemma; Masao Harada; Hirohisa Yoshizawa; Ichiro Kinoshita; Yuka Fujita; Shoji Okinaga; Haruto Hirano; Kozo Yoshimori; Toshiyuki Harada; Takashi Ogura; Masahiro Ando; Hitoshi Miyazawa; Tomoaki Tanaka; Yasuo Saijo; Koichi Hagiwara; Satoshi Morita; Toshihiro Nukiwa
Journal:  N Engl J Med       Date:  2010-06-24       Impact factor: 91.245

4.  Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial.

Authors:  Tetsuya Mitsudomi; Satoshi Morita; Yasushi Yatabe; Shunichi Negoro; Isamu Okamoto; Junji Tsurutani; Takashi Seto; Miyako Satouchi; Hirohito Tada; Tomonori Hirashima; Kazuhiro Asami; Nobuyuki Katakami; Minoru Takada; Hiroshige Yoshioka; Kazuhiko Shibata; Shinzoh Kudoh; Eiji Shimizu; Hiroshi Saito; Shinichi Toyooka; Kazuhiko Nakagawa; Masahiro Fukuoka
Journal:  Lancet Oncol       Date:  2009-12-18       Impact factor: 41.316

5.  A double-blind, randomised, placebo-controlled phase III intergroup study of gefitinib in patients with advanced NSCLC, non-progressing after first line platinum-based chemotherapy (EORTC 08021/ILCP 01/03).

Authors:  Rabab M Gaafar; Veerle F Surmont; Giorgio V Scagliotti; Rob J Van Klaveren; Demetris Papamichael; John J Welch; Baktiar Hasan; Valter Torri; Jan P van Meerbeeck
Journal:  Eur J Cancer       Date:  2011-07-28       Impact factor: 9.162

6.  2011 Focused Update of 2009 American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non-Small-Cell Lung Cancer.

Authors:  Christopher G Azzoli; Sarah Temin; Timothy Aliff; Sherman Baker; Julie Brahmer; David H Johnson; Janessa L Laskin; Gregory Masters; Daniel Milton; Luke Nordquist; William Pao; David G Pfister; Steven Piantadosi; Joan H Schiller; Reily Smith; Thomas J Smith; John R Strawn; David Trent; Giuseppe Giaccone
Journal:  J Clin Oncol       Date:  2011-09-06       Impact factor: 44.544

7.  Gefitinib versus placebo as maintenance therapy in patients with locally advanced or metastatic non-small-cell lung cancer (INFORM; C-TONG 0804): a multicentre, double-blind randomised phase 3 trial.

Authors:  Li Zhang; Shenglin Ma; Xiangqun Song; Baohui Han; Ying Cheng; Cheng Huang; Shujun Yang; Xiaoqing Liu; Yunpeng Liu; Shun Lu; Jie Wang; Shucai Zhang; Caicun Zhou; Xiangwei Zhang; Nobuya Hayashi; Mengzhao Wang
Journal:  Lancet Oncol       Date:  2012-04-17       Impact factor: 41.316

8.  Phase III study of immediate compared with delayed docetaxel after front-line therapy with gemcitabine plus carboplatin in advanced non-small-cell lung cancer.

Authors:  Panos M Fidias; Shaker R Dakhil; Alan P Lyss; David M Loesch; David M Waterhouse; Jane L Bromund; Ruqin Chen; Maria Hristova-Kazmierski; Joseph Treat; Coleman K Obasaju; Martin Marciniak; John Gill; Joan H Schiller
Journal:  J Clin Oncol       Date:  2008-12-15       Impact factor: 44.544

9.  Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study.

Authors:  Tudor Ciuleanu; Thomas Brodowicz; Christoph Zielinski; Joo Hang Kim; Maciej Krzakowski; Eckart Laack; Yi-Long Wu; Isabel Bover; Stephen Begbie; Valentina Tzekova; Branka Cucevic; Jose Rodrigues Pereira; Sung Hyun Yang; Jayaprakash Madhavan; Katherine P Sugarman; Patrick Peterson; William J John; Kurt Krejcy; Chandra P Belani
Journal:  Lancet       Date:  2009-09-18       Impact factor: 79.321

10.  Randomized phase III trial of platinum-doublet chemotherapy followed by gefitinib compared with continued platinum-doublet chemotherapy in Japanese patients with advanced non-small-cell lung cancer: results of a west Japan thoracic oncology group trial (WJTOG0203).

Authors:  Koji Takeda; Toyoaki Hida; Tosiya Sato; Masahiko Ando; Takashi Seto; Miyako Satouchi; Yukito Ichinose; Nobuyuki Katakami; Nobuyuki Yamamoto; Shinzoh Kudoh; Jiichiro Sasaki; Kaoru Matsui; Koichi Takayama; Tatsuhiko Kashii; Yasuo Iwamoto; Toshiyuki Sawa; Isamu Okamoto; Takayasu Kurata; Kazuhiko Nakagawa; Masahiro Fukuoka
Journal:  J Clin Oncol       Date:  2009-12-28       Impact factor: 44.544
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.